Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

@article{Hsu1997TumorspecificIV,
  title={Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.},
  author={Frank J. Hsu and Clemens B. Caspar and Debra D Czerwinski and Alfred L. Garfall and Tina Marie Liles and Athanasia D. Syrengelas and Behnaz Taidi-Laskowski and Ronald N. Levy},
  journal={Blood},
  year={1997},
  volume={89 9},
  pages={
          3129-35
        }
}
The surface Ig on each B-cell lymphoma has unique portions (idiotypes), which can be recognized by the immune system. In this study, we immunized patients against the Ig expressed by their tumor and observed their clinical outcomes. After standard chemotherapy, 41 patients with non-Hodgkin's B-cell lymphoma received a series of injections with a vaccine consisting of tumor Ig protein coupled to keyhole limpet hemocyanin and emulsified in an immunologic adjuvant. Subjects were observed for… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 191 CITATIONS, ESTIMATED 56% COVERAGE

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2008
VIEW 8 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 5 EXCERPTS
CITES RESULTS, METHODS & BACKGROUND
HIGHLY INFLUENCED

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

  • Cancer research
  • 2002
VIEW 4 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1998
2018

CITATION STATISTICS

  • 5 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Mouse 1 humanmacrophage colony - stimulating factor

RA Miller, DG Maloney, R Warnke, R Levy
  • J Immunol
  • 1994

National Cancer Institute sponsored study of classifications ofstimulating factor fusion protein as a vaccine for B - cell lymphoma

TT Chen, MH Tao, R Levy
  • Nature
  • 1993

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and and haematological neoplasia

R McElderry, T Basham, RA Warnke, TC Merigan, R Levy
  • Br J Biomed Sci 50:135,
  • 1993

Monoclonal anti-idiotype antibodies against the murine B cell lymphoma: Evidence for antigen selection

DG Maloney, MS Kaminski, D Burowski, J Haimovich, R Levy
  • Proc Natl Acad Sci USA
  • 1992

gence of idiotypenegative variant cells

SL Brown, RA Miller, +8 authors AC Newland
  • Blood
  • 1992

lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

MJ Campbell, L Esserman, NE Byars, AC Allison, R Levy
  • N Engl J Med
  • 1992

Claybergerin combination with alpha interferon

TC Meeker, J Lowder, +3 authors AM Krensky
  • Blood
  • 1989